Enveric Biosciences (ENVB) Times Interest Earned (2013 - 2025)
Enveric Biosciences (ENVB) posted Times Interest Earned of -$66.7 for Q4 2025, up 34.06% sequentially from -$101.15 in Q4 2024, and up 34.06% YoY from -$49.75 in Q4 2024.
Enveric Biosciences (ENVB) Times Interest Earned (2013 - 2025) Analysis & Trends
Enveric Biosciences has reported Times Interest Earned for 13 years, with the latest figure at -$66.7 in Q4 2025.
- Quarterly Times Interest Earned rose 34.06% year-over-year to -$66.7 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$266.77 (up 13.1% YoY) and the FY2025 annual result came in at -$266.77, down 426.2% from the prior year.
- Times Interest Earned rose to -$66.7 in Q4 2025 per ENVB's latest filing, from -$101.15 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.19 in Q4 2023 and troughed at -$441879.8 in Q1 2023.
- A 5-year average of -$47450.4 and a median of -$630.07 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned slumped 381361.79% in 2022, then soared 100.0% in 2023.
- Over 5 years, Times Interest Earned stood at -$9947.0 in 2021, then plunged by 812.66% to -$90782.6 in 2022, then jumped by 100.0% to -$0.19 in 2023, then sank by 54363.15% to -$101.15 in 2024, then surged by 34.06% to -$66.7 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$66.7, -$101.15, and -$0.19 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -66.70 |
| Dec 31, 2024 | -101.15 |
| Dec 31, 2023 | -0.19 |
| Mar 31, 2023 | -441,879.82 |
| Dec 31, 2022 | -90,782.61 |
| Sep 30, 2022 | -18,366.39 |
| Jun 30, 2022 | -7,046.05 |
| Mar 31, 2022 | -1,158.98 |
| Dec 31, 2021 | -9,947.03 |
| Sep 30, 2021 | -4.81 |
| Jun 30, 2021 | -40.80 |
| Mar 31, 2021 | -10.63 |
| Dec 31, 2020 | -61.70 |
| Sep 30, 2020 | -0.55 |
| Jun 30, 2020 | -0.84 |
| Mar 31, 2020 | -3.20 |
| Dec 31, 2019 | -4.35 |
| Sep 30, 2019 | -6.15 |
| Jun 30, 2019 | -4.66 |
| Mar 31, 2019 | -9.06 |